Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Price

Click to order products ascending

Display 15 Products per page

Entyvio
Read More
Entyvio (vedolizumab; Takeda) is a humanized monoclonal antibody approved for the treatment of Crohn’s disease and ulcerative colitis.
August 2, 2018
Find out more
Etrolizumab
Read More
Etrolizumab (Roche) is a humanized anti-beta 7 integrin subunit monoclonal antibody in Phase III development for the treatment of ulcerative colitis.
August 2, 2018
Find out more
Jevtana
Read More
Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.
January 18, 2018
Find out more
TAK-003
Read More
TAK-003 (Takeda) is a needle-free, tetravalent live-attenuated vaccine currently in Phase II/III development in the US and dengue-endemic countries in Asia and Latin America, including Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Peru, the Philippines, Sri Lanka, Thailand, and Vietnam.
January 4, 2018
Find out more
TetraVax-DV
Read More
TetraVax-DV is a lyophilized, tetravalent, live-attenuated chimeric vaccine currently in Phase II/III development.
January 4, 2018
Find out more
Tivicay
Read More
Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Neupro
Read More
Neupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours and avoids the fluctuation in dopaminergic stimulation resulting from numerous oral doses
June 21, 2018
Find out more
Tracleer
Read More
Actelion’s Tracleer (bosentan) was the first oral therapy to be developed specifically for the treatment of pulmonary arterial hypertension (PAH).
October 29, 2018
Find out more
Nouriast
Read More
Nouriast (istradefylline; Kyowa Hakko Kirin) is the first, and so far, the only adenosine A2a receptor antagonist to be approved for the treatment of Parkinson’s disease. It acts to decrease overactivity of the indirect pathway of the motor circuit that is present in Parkinson’s disease patients with low dopamine levels.
June 21, 2018
Find out more
Triumeq
Read More
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
June 28, 2019
Find out more
Ublituximab
Read More
Ublituximab (TG Therapeutics) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications.
January 31, 2019
Find out more
Prezista franchise
Read More
The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson) and the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded as Prezcobix in the US and Rezolsta in the EU.
June 28, 2019
Find out more
Uptravi
Read More
Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
V180
Read More
Merck & Co’s adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes (DEN-1 strain 258848, DEN-2 strain PR159 S1, DEN-3 strain CH53489, and DEN-4 strain H241).
January 4, 2018
Find out more
Vigil
Read More
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
October 30, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *